{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:27:09Z","timestamp":1770341229643,"version":"3.49.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.radonc.2016.03.013","type":"journal-article","created":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T08:30:20Z","timestamp":1460449820000},"page":"423-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Normal tissue considerations and dose\u2013volume constraints in the moderately hypofractionated treatment of non-small cell lung cancer"],"prefix":"10.1016","volume":"119","author":[{"given":"Cathy","family":"Fleming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5167-0213","authenticated-orcid":false,"given":"Daniel N.","family":"Cagney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"O\u2019Keeffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinead M.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"McClean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2016.03.013_b0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0010","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2016.03.013_b0015","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z","article-title":"Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report of the Radiation Therapy Oncology Group","volume":"59","author":"Perez","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.117.2.358","article-title":"Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group","volume":"117","author":"Sause","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.radonc.2016.03.013_b0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijrobp.2005.02.010","article-title":"High-dose radiation improved local tumor control and overall survival in patients with inoperable\/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study","volume":"63","author":"Kong","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JTO.0b013e3181915028","article-title":"Late complications of high-dose (\u2a7e66Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer","volume":"4","author":"Lee","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0035","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2005.03.037","article-title":"Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience","volume":"63","author":"Machtay","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.radonc.2003.09.006","article-title":"Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy","volume":"71","author":"Thirion","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0045","series-title":"CG121: The diagnosis and treatment of lung cancer","author":"NICE","year":"2011"},{"key":"10.1016\/j.radonc.2016.03.013_b0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2013.07.014","article-title":"Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres","volume":"109","author":"Din","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0055","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0169-5002(16)30151-9","article-title":"Long term local tumour control in inoperable NSCLC treated with accelerated hypofractionated radiotherapy and concurrent cisplatinum and vinorelbine","volume":"91","author":"Kelly","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0060","unstructured":"Kong F-MS, Machtay M, Bradley JD, Ten Haken RK, Xiao Y, Matuszak MM, et al. RTOG 1106\/ACRIN 6697 Randomized phase II trial of individualized adaptive radiotherapy using during treatment FDG-PET\/CT and modern technology in locally advanced non-small cell lung cancer (NSCLC). 2013."},{"key":"10.1016\/j.radonc.2016.03.013_b0065","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S0169-5002(14)70149-7","article-title":"Dose escalation in the I-START trial \u2013 ISoToxic Accelerated RadioTherapy in locally advanced non-small cell lung cancer","volume":"83","author":"Nixon","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0070","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.ijrobp.2013.12.034","article-title":"Optimizing collimator margins for isotoxically dose-escalated conformal radiation therapy of non-small cell lung cancer","volume":"88","author":"Warren","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0075","first-page":"106","article-title":"Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25","author":"Cheung","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2016.03.013_b0080","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cllc.2014.10.005","article-title":"Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation","volume":"16","author":"Swanick","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0090","doi-asserted-by":"crossref","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.radonc.2008.07.032","article-title":"Isodose-based methodology for minimizing the morbidity and mortality of thoracic hypofractionated radiotherapy","volume":"91","author":"Gay","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clon.2014.03.011","article-title":"An isotoxic planning comparison study for stage II\u2013III non-small cell lung cancer: Is intensity-modulated radiotherapy the answer?","volume":"26","author":"Warren","year":"2014","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2006.04.034","article-title":"Final results of a phase I\/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy","volume":"66","author":"Belderbos","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0110","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijrobp.2004.06.260","article-title":"Toxicity and outcome results of RTOG 9311: a phase I\u2013II dose\u2013escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma","volume":"61","author":"Bradley","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijrobp.2004.02.066","article-title":"Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?","volume":"61","author":"Miller","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/S0360-3016(99)00183-2","article-title":"Clinical dose\u2013volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer","volume":"45","author":"Graham","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.radonc.2013.08.017","article-title":"Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy","volume":"108","author":"Chen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0130","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1200\/JCO.2013.51.5353","article-title":"Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer","volume":"31","author":"Cannon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/153303460800700605","article-title":"Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I","volume":"7","author":"Adkison","year":"2008","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.radonc.2016.03.013_b0140","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ijrobp.2006.01.051","article-title":"Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis","volume":"65","author":"Kong","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0145","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijrobp.2008.10.020","article-title":"A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study","volume":"74","author":"Cho","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0150","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.ijrobp.2009.06.075","article-title":"Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy","volume":"77","author":"Bral","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0155","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/JTO.0b013e3181a97dda","article-title":"Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer","volume":"4","author":"Kepka","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0160","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1748-717X-9-190","article-title":"Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer","volume":"9","author":"Kerner","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0165","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/JTO.0b013e31828cb6db","article-title":"Hypofractionated three-dimensional conformal radiation therapy alone for centrally located cT1-3N0 Non-Small-Cell Lung Cancer","volume":"8","author":"Oh","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0170","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.ejca.2014.07.009","article-title":"SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status","volume":"50","author":"Maguire","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-8-201","article-title":"Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy\/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer : a phase I trial","volume":"8","author":"Lin","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fonc.2013.00286","article-title":"Moderately escalated hypofractionated (chemo) radiotherapy delivered with helical intensity-modulated technique in stage III unresectable non-small cell lung cancer","volume":"3","author":"Donato","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0185","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2006.09.005","article-title":"Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)","volume":"43","author":"Belderbos","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0190","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0167-8140(12)72714-7","article-title":"Escalated dose for Non-Small-Cell Lung Cancer with accelerated hypofractionated three-dimensional conformal radiation therapy","volume":"92","author":"Thirion","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0195","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3747\/co.19.976","article-title":"Outcomes of accelerated hypofractionated radiotherapy in stage I non-small-cell lung cancer","volume":"19","author":"Yung","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0200","unstructured":"ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I\/II I-START Trial (I-START) n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01537991."},{"key":"10.1016\/j.radonc.2016.03.013_b0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijrobp.2012.10.012","article-title":"Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer","volume":"85","author":"Osti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lungcan.2009.03.023","article-title":"Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I-II non-small-cell lung cancer","volume":"67","author":"Bonfili","year":"2010","journal-title":"Lung cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0215","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1186\/1471-2407-13-513","article-title":"Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen","volume":"13","author":"Bearz","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0220","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s10147-009-0889-0","article-title":"Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin\/paclitaxel in the treatment of locally advanced non-small-cell lung cancer","volume":"14","author":"Matsuura","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0225","first-page":"S171","article-title":"Changes in pulmonary functions after radical accelerated hypofractionatad radiotherapy concurrent with cisplatinum and vinoraibine","volume":"49","author":"Maguire","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0230","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0360-3016(97)00584-1","article-title":"Fraction size and dose parameters related to the incidence of pericardial effiusions","volume":"40","author":"Martel","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0235","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2014.02.011","article-title":"Pulmonary artery invasion, high-dose radiation, and overall survival in patients with non-small cell lung cancer","volume":"89","author":"Han","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0240","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0936-6555(96)80042-2","article-title":"Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The medical research council lung cancer working party","volume":"8","author":"Macbeth","year":"1996","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0245","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3109\/0284186X.2010.498835","article-title":"Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques","volume":"49","author":"Vogelius","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0250","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijrobp.2013.10.015","article-title":"Alpha\/beta ratio for normal lung tissue as estimated from lung cancer patients treated with stereotactic body and conventionally fractionated radiation therapy","volume":"88","author":"Scheenstra","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0255","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/095530000138448","article-title":"Quantitative clinical radiobiology of early and late lung reactions","volume":"76","author":"Bentzen","year":"2000","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.radonc.2016.03.013_b0260","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2006.12.031","article-title":"Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy","volume":"68","author":"Yom","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0265","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ijrobp.2006.03.012","article-title":"Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma","volume":"65","author":"Allen","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0270","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2004.06.007","article-title":"Dosimetric verification of a commercial collapsed cone algorithm in simulated clinical situations","volume":"73","author":"Nisbet","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0275","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1120\/jacmp.v14i5.4316","article-title":"Influence of different dose calculation algorithms on the estimate of NTCP for lung complications","volume":"14","author":"Hedin","year":"2013","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-8140(03)00195-6","article-title":"Incorporating an improved dose-calculation algorithm in conformal radiotherapy of lung cancer: re-evaluation of dose in normal lung tissue","volume":"69","author":"De Jaeger","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0285","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clon.2003.11.014","article-title":"The clinical Implications of the collapsed cone planning algorithm","volume":"16","author":"Irvine","year":"2004","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2009.05.070","article-title":"Radiation dose\u2013volume effects in the esophagus","volume":"76","author":"Werner-Wasik","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0295","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijrobp.2013.07.029","article-title":"Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis","volume":"87","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0300","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clon.2008.10.003","article-title":"Oesophageal toxicity and hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer","volume":"21","author":"Tho","year":"2009","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0305","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","article-title":"Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis","volume":"85","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.03.013_b0310","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.radonc.2008.09.010","article-title":"Systematic review of dose\u2013volume parameters in the prediction of esophagitis in thoracic radiotherapy","volume":"91","author":"Rose","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.03.013_b0315","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0169-5002(12)70153-8","article-title":"Clinical prediction for acute toxicity in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiation","volume":"75","author":"Uyterlinde","year":"2012","journal-title":"Lung cancer"},{"key":"10.1016\/j.radonc.2016.03.013_b0320","article-title":"ICRU 83. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT)","volume":"10","author":"Gregoire","year":"2010","journal-title":"J ICRU"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814016310209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814016310209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T08:21:47Z","timestamp":1536826907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814016310209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0167814016310209"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2016.03.013","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Normal tissue considerations and dose\u2013volume constraints in the moderately hypofractionated treatment of non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2016.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}